By Memorandum Opinion entered in Allergan USA, Inc. et al. v. Aurobindo Pharma Ltd., et al., Civil Action No. 19-1727-RGA (D.Del. January 11, 2021), The Honorable Richard G. Andrews construed the five (5) remaining terms in dispute in the six (6) patents-in-suit, U.S. Patent Nos. 8,691,860 (“the ‘860 patent”), 9,115,091 (“the ‘091 patent”), 9,364,489 (“the ‘489 patent”), 9,789,125 (“the ‘125 patent”), 9,675,587 (“the ‘587 patent”) and 10,188,632 (“the ‘632 patent”), in a Hatch-Waxman action concerning Plaintiffs’ VIBERZI® brand (eluxadoline) products for the treatment of irritable bowel syndrome with diarrhea.
A complete copy of the Memorandum Opinion is attached.